BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1757 related articles for article (PubMed ID: 11522637)

  • 21. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo.
    Zhao T; Rao XM; Xie X; Li L; Thompson TC; McMasters KM; Zhou HS
    Cancer Res; 2003 Jun; 63(12):3073-8. PubMed ID: 12810631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
    Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma].
    Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Xu JM; Qian YZ; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):468-72. PubMed ID: 15854553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
    Yu DC; Chen Y; Seng M; Dilley J; Henderson DR
    Cancer Res; 1999 Sep; 59(17):4200-3. PubMed ID: 10485454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
    Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
    Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene.
    Kanai F; Lan KH; Shiratori Y; Tanaka T; Ohashi M; Okudaira T; Yoshida Y; Wakimoto H; Hamada H; Nakabayashi H; Tamaoki T; Omata M
    Cancer Res; 1997 Feb; 57(3):461-5. PubMed ID: 9012474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
    Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O; Morris JC
    Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomerase-dependent oncolytic adenovirus for cancer treatment.
    Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
    Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter.
    Sagawa T; Takahashi M; Sato T; Sato Y; Lu Y; Sumiyoshi T; Yamada Y; Iyama S; Fukaura J; Sasaki K; Hamada H; Miyanishi K; Takayama T; Kato J; Niitsu Y
    Mol Ther; 2004 Dec; 10(6):1043-50. PubMed ID: 15564136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro gene therapy of hepatocellular carcinoma using replication-defective and tumor-specific replication-competent adenovirus carrying interleukin-12 gene].
    Wang XH; Yang JM; Cui ZF; Wang WG; Wu MC; Qian QJ
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):581-4. PubMed ID: 15634515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J; Cho JY; Kim JH; Jung KC; Yun CO
    Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
    Ma XJ; Huang R; Kuang AR
    Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 88.